Clinical Trial Update: Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA [Phase 2]

View source ↗

Summary

Phase 2 study evaluating adding pracinostat to a hypomethylating agent in patients with myelodysplastic syndrome who did not respond to single-agent HMA; the tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Pracinostat (pracinostat)

Snippet

Sponsor: Helsinn Healthcare SA | Conditions: Myelodysplastic Syndrome, MDS | Phase 2 | Status: COMPLETED